Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

STAT3 is a transcription factor involved in cytokine and receptor kinase signal transduction that is aberrantly activated in a variety of sarcomas, promoting metastasis and chemotherapy resistance. The purpose of this work was to develop and test a novel putative STAT3 inhibitor, LY5.An in silico fr...

Full description

Bibliographic Details
Main Authors: Peter Y Yu, Heather L Gardner, Ryan Roberts, Hakan Cam, Seethalakshmi Hariharan, Ling Ren, Amy K LeBlanc, Hui Xiao, Jiayuh Lin, Denis C Guttridge, Xiaokui Mo, Chad E Bennett, Christopher C Coss, Yonghua Ling, Mitch A Phelps, Peter Houghton, Cheryl A London
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5531494?pdf=render

Internet

http://europepmc.org/articles/PMC5531494?pdf=render

Similar Items